IDEAS home Printed from https://ideas.repec.org/p/bjn/evalua/accelvax-e2.html
   My bibliography  Save this paper

Evaluation 2 of "Accelerating Vaccine Innovation for Emerging Infectious Diseases via Parallel Discovery"

Author

Listed:
  • Tim Colbourn

Abstract

This paper tackles an important global priority area. The main limitations are the premise being restricted to private sector investment, and parameter values used. A societal perspective including (up to 100%) publicly owned efforts, and different reasonable parameter value assumptions, including optimising number of vaccine candidates in relation to expected outbreaks and infections, would alter the conclusions. Calculating cost per QALY gained, and in relation to current healthcare expenditure, would further strengthen the paper.

Suggested Citation

  • Tim Colbourn, 2024. "Evaluation 2 of "Accelerating Vaccine Innovation for Emerging Infectious Diseases via Parallel Discovery"," The Unjournal Evaluations 2024-12, The Unjournal.
    • Handle: RePEc:bjn:evalua:accelvax-e2
    DOI: 10.21428/d28e8e57.59b7c04e/89842a46
    as

    Download full text from publisher

    File URL: https://unjournal.pubpub.org/pub/accelvaxeval2
    Download Restriction: no
    File URL: https://libkey.io/10.21428/d28e8e57.59b7c04e/89842a46?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Arthur E. Attema & Werner B. F. Brouwer & Karl Claxton, 2018. "Discounting in Economic Evaluations," PharmacoEconomics, Springer, vol. 36(7), pages 745-758, July.
    2. Joseph Barberio & Jacob Becraft & Zied Ben Chaouch & Dimitris Bertsimas & Tasuku Kitada & Michael L. Li & Andrew W. Lo & Kevin Shi & Qingyang Xu, 2022. "Accelerating Vaccine Innovation for Emerging Infectious Diseases via Parallel Discovery," NBER Chapters, in: Entrepreneurship and Innovation Policy and the Economy, volume 2, pages 9-39, National Bureau of Economic Research, Inc.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Steve Harris & Jan Weinzettel & Gregor Levin, 2020. "Implications of Low Carbon City Sustainability Strategies for 2050," Sustainability, MDPI, vol. 12(13), pages 1-23, July.
    2. Błażej Łyszczarz & Karolina Sowa, 2022. "Production losses due to mortality associated with modifiable health risk factors in Poland," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(1), pages 33-45, February.
    3. Islas-Aguirre, Juan Francisco & Venegas-Martínez, Francisco, 2024. "Interacción entre apoyos monetarios agrícolas y pobreza en los estados de mayor producción agrícola en México (2020), un enfoque de econometría espacial," Panorama Económico, Escuela Superior de Economía, Instituto Politécnico Nacional, vol. 19(40), pages 203-231, Primer se.
    4. Klas Kellerborg & Werner Brouwer & Pieter Baal, 2020. "Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literature," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(9), pages 1329-1350, December.
    5. Kimberly M. Thompson & Dominika A. Kalkowska, 2021. "Potential Future Use, Costs, and Value of Poliovirus Vaccines," Risk Analysis, John Wiley & Sons, vol. 41(2), pages 349-363, February.
    6. David Manheim & David Reinstein & Richard Bruns & Tim Colbourn, 2024. "Evaluation Summary and Metrics: "Accelerating Vaccine Innovation for Emerging Infectious Diseases via Parallel Discovery"," The Unjournal Evaluations 2024-10, The Unjournal.
    7. Lars Hultkrantz, 2021. "Discounting in economic evaluation of healthcare interventions: what about the risk term?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(3), pages 357-363, April.
    8. Ali Tafazzoli & Odette S. Reifsnider & Leana Bellanca & Jack Ishak & Marc Carrasco & Pal Rakonczai & Matthew Stargardter & Stephan Linden, 2023. "A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(9), pages 1441-1454, December.
    9. Elahe Khorasani & Majid Davari & Abbas Kebriaeezadeh & Farshad Fatemi & Ali Akbari Sari & Vida Varahrami, 2022. "A comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(9), pages 1577-1590, December.
    10. Werner Brouwer & Pieter Baal & Job Exel & Matthijs Versteegh, 2019. "When is it too expensive? Cost-effectiveness thresholds and health care decision-making," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 175-180, March.
    11. Sujata Behera, 2020. "Does the EVA valuation model explain the market value of equity better under changing required return than constant required return?," Financial Innovation, Springer;Southwestern University of Finance and Economics, vol. 6(1), pages 1-23, December.
    12. Admassu N. Lamu & Ole F. Norheim & Fredrik A. Gregersen & Mathias Barra, 2021. "Cycle‐network expansion plan in Oslo: Modeling cost‐effectiveness analysis and health equity impact," Health Economics, John Wiley & Sons, Ltd., vol. 30(12), pages 3220-3235, December.
    13. Silke Gabbert & Arianne de Blaeij & Joris T. K. Quik & Joost Bakker & Joop de Knecht & Eric Verbruggen & Richard Luit, 2023. "Can cost‐effectiveness analysis of control measures for persistent chemicals be improved? A critical evaluation of approaches for assessing “effectiveness”," Journal of Industrial Ecology, Yale University, vol. 27(1), pages 155-169, February.
    14. Gaurab Aryal & Federico Ciliberto & Leland E. Farmer & Ekaterina Khmelnitskaya, 2022. "Valuing Pharmaceutical Drug Innovations," Papers 2212.07384, arXiv.org, revised Apr 2024.
    15. Himmler, Sebastian & Jonker, Marcel & van Krugten, Frédérique & Hackert, Mariska & van Exel, Job & Brouwer, Werner, 2022. "Estimating an anchored utility tariff for the well-being of older people measure (WOOP) for the Netherlands," Social Science & Medicine, Elsevier, vol. 301(C).
    16. Kellerborg, Klas & Wouterse, Bram & Brouwer, Werner & van Baal, Pieter, 2021. "Estimating the costs of non-medical consumption in life-years gained for economic evaluations," Social Science & Medicine, Elsevier, vol. 289(C).

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bjn:evalua:accelvax-e2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Davit Jintcharadze (email available below). General contact details of provider: https://unjournal.org/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.